RE:RE:RE:RE:RE:RE:RE:Let me try again.....
99942Apophis wrote: Thank you CancerSlayer for that answer. Your comparison to overuse with antibiotics sends a clear picture of how to render a great medical treatment into a non effective one in the whack a mole overuse, however in an attempt to ward off death whack a mole is still a viable option perhaps in a limited consideration.
AUA being held in Chicago could bring media attention to Theralase, a few posters here have expressed hope that such exposure will increase buying. TLT is currently shining very bright with their rising CR & durability and media exposure in my opinion will bring in more buyers but from what I've seen so far it might be slow until we start hitting local news coverage with Theralase's spokespeople. We can only go up from here eh!
Yes...I didn't intend to discount the need for repeated treatments in many instances. Historically, such an approach has proven itself. I was just highlighting the potential drawbacks of such an approach. This is where I believe combining therapies that use different pathways/mechanisms of action &/or delivery methods can perhaps improve overall treatment success. Being able to attack cancer from different angles with the least number of doses may offer the best chance for a durable response/recurrence-free survival. Unfortunately, multiple treatments using the same or similar MoA (with their concomitant side effects/impact on quality of life) have become a type of necessary evil in improving overall survival for many patients.
The combo impact of the AUA & an eventual BTD will bring much needed attention to this little biotech in ways we have never seen. All trends point to a very successful future...I am already planning for my Vegas trip.